Merrimack still ambitious for IPO as others wait in the wings
This article was originally published in Scrip
Executive Summary
Merrimack Pharmaceuticals is aiming to raise $133-167 million in its initial public offering on Nasdaq, possibly rising up to $192 million if underwriters exercise an option to purchase up to 2.5 million additional shares. That would be more than the $172.5 million upper limit it set at the time of filing last July (scripintelligence.com, 13 July 2011).